You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股午評:恆指跌破23000創一年半以來新低,恆生科技指數跌超2%

港股三大指數集體重挫,恆指跌1.44%至22859點續刷調整新低;恆生科技指數跌2.42%報5543點,再刷歷史新低;國指跌1.45%報8099點。南下資金半日淨流入25.43億港元,大市半日成交額為636億港元。 

盤面上,大型科技股繼續重挫,網易跌超6%,京東跌近4%,騰訊、快手、美團跌超1%,嗶哩嗶哩、百度、阿里跟跌;港股特斯拉概念股領跌港股,億和控股跌超15%;風電股、電力設備股、光伏股等新能源股幅靠前;稀土概念、教育股、體育用品、內房股等股集體重挫;有色金屬股回調走弱。 另一方面,中醫藥管理局稱新冠本土感染者普遍應用了中醫藥,中醫藥概念股集體上漲;豬肉概念、乳製品股、航運及港口、旅遊觀光股逆市走強。

港股特斯拉概念股集體下挫 億和控股(0838.HK)跌超15%

特斯拉概念股集體下挫,其中,億和控股跌超15%領跌,贛鋒鋰業跌超8%,力勁科技跌近5%,比亞迪股份、雅迪控股和耐世特跌超3%。

中藥股集體上漲 中醫藥管理局稱新冠本土感染者普遍應用了中醫藥

中藥股集體大漲,其中隴神戎發,維康藥業,紫鑫藥業,佛慈制藥,盤龍藥業,濟川藥業漲停,羚鋭製藥漲8%,新光藥業,健民集團漲7%;港股白雲山,同仁堂國藥漲月3%,中國中藥漲1%。 消息面上,國家中醫藥管理局在16日的新聞發佈會上稱,新冠肺炎疫情發生以來,目前,新冠肺炎本土確診病例和無症狀感染者中,除個別特殊情況人員外,均普遍應用了中醫藥。中醫藥治療在改善患者臨牀症狀等方面發揮了重要作用。國家中醫藥管理局應對新冠肺炎疫情防控工作領導小組專家組副組長張忠德介紹,專家組經過綜合分析研判認為,本輪疫情仍屬於中醫“疫病”範疇,中醫的核心病因病機沒有大的改變,還是屬於濕毒鬱閉,中醫藥為主治療仍然有效。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account